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 Objectives: Sex differences in COVID-19 severity and mortality have been described.  Key aims of 
this analysis were to compare the risk of invasive mechanical ventilation (IMV) and mortality by 
sex and to explore whether variation in specific biomarkers could mediate this difference. 
Methods: This was a retrospective, observational cohort study among patients with severe COVID-
19 pneumonia. A survival analysis was conducted to compare time to the composite endpoint of 
IMV or death by sex. Interaction was formally tested to compare the risk difference by sex in 
subsets. Mediation analysis with a binary endpoint IMV or death (yes/no) by end of follow-up for a 
number of inflammation/coagulation biomarkers in the context of counterfactual prediction was 
also conducted.    
 Results: Among 415 patients, 134 were females (32%) and 281 males (67%), median age 66 years 
(IQR 54-77). At admission, females showed a significantly less severe clinical and respiratory 
profiles with a higher PaO2/FiO2 (254 mmHg vs 191 mmHg; p=0.023). By 28 days from admission, 
49.2% (95% CI: 39.6-58.9%) of males vs. 31.7% (17.9-45.4%) of females underwent IMV or death 
(log-rank p-value<0.0001) and this amounted to a difference in HR of 0.40 (0.26-0.63, p=0.0001). 
The AUC in C-reactive protein (CRP) over the study period appeared to explain 85% of this 
difference in risk by sex.  
 Conclusions: Our analysis confirms a difference in the risk of COVID-19 clinical progression by sex 
and provides a hypothesis for potential mechanisms leading to this. CRP showed a predominant 











Clinical spectrum of COVID-19 is heterogeneous ranging from asymptomatic cases to severe 
diseases (1-3). Reported mortality rate of COVID-19 ranges between 1.4% to 61%  (4-6).  Main risk 
factors for poor prognosis are: male sex, ethnicity, age >65 years, overweight and pre-existing co-
morbidities (5,7-9). Indeed, women seem to be protected from developing a severe disease 
(4,10,11), intensive care unit (ICU) admission and mortality (1,5,6,12). A recent study also showed 
a significant difference by sex in laboratory parameters abnormalities, playing a mediation effect 
on prognosis (13).  
Several mechanisms have been hypothesised. A difference by sex expression/function of 
angiotensin converting enzyme 2 (ACE2), the host cell receptor of the virus, was found in both 
animal models and in humans. Male mice are more susceptible to severe acute respiratory 
syndrome-coronavirus-1 (SARS-CoV-1) infection than age-matched females, but this protection is 
lost after ovariectomy (14), implying a pivotal role of sex hormones (15). In humans, Asian men 
showed higher ACE2 expression than women (16).  
From an immunological perspective, females mount stronger innate and adaptive immune 
responses than males, resulting in faster clearance of pathogens parallel to an increased 
susceptibility to autoimmune diseases (17). 
The aim of this analysis is two-fold: first to compare the risk of invasive mechanical ventilation 
(IMV) and mortality by sex and second, to explore whether variation in specific biomarkers could 
mediate this difference. 
Methods 
This was a retrospective, observational cohort study carried out at the University Hospital of 
Modena, Italy among patients admitted to hospital between 21 February and 25 May 2020 for 
severe COVID-19 pneumonia. The study was approved by the regional ethical committee. All 
consecutively enrolled adult patients (≥18 years) with severe COVID-19 pneumonia, defined by the 
presence of at least one of the following: a respiratory rate (RR) ≥30 breaths per minute (bpm), 
peripheral blood oxygen saturation (SaO2) ≤ 93%, a PaO2/FiO2 ratio <300 mmHg in room air and 
lung infiltrates >50% within 24-48 hours were included in the study (18,19). 
Patients were treated according to standard of care (SoC) consisting of hydroxychloroquine, 
lopinavir and low molecular weight heparin and a non-randomly selected subset of patients 











The primary outcome of the study was the composite endpoint of IMV or death; the secondary 
outcome was all-cause mortality.  
Statistical analysis 
Baseline characteristics of the participants were compared according to sex. Continuous variables 
were expressed as median (IQR) and compared by Mann-Whitney U test. Categorical variables 
were expressed as numbers (%) and compared by χ
2
 test or Fisher’s exact test by sex.  
 Standard survival analysis was performed with participants’ follow-up accrued from the date of 
hospital entry until initiation of IMV or death by means of unweighted Kaplan-Meier curves and 
univariable Cox regression analysis. The effect of sex  is shown by means of unadjusted  hazard 
ratio (HR) with 95% confidence intervals (CI) from fitting an unadjusted standard Cox regression 
model. The key assumption was that sex was un-confounded so only univariable analyses were 
performed. This assumption was tested in the data by fitting a multivariable model adjusting for 
potential confounding factors and results are shown as Supplemental Material (Supplementary 
Figure S3 and Table S2)The sex effect was further evaluated in subsets of the study population 
(stratified by extent of existing co-morbidities, age, post baseline glucocorticoids use, BMI and use 
of tocilizumab, respectively) and the HRs in the strata were shown in a forest plot and formally 
compared using an interaction test in the Cox regression model.  
For the mediation analysis, the time to event framework was simplified to the risk of developing 
the primary outcome by  day 28 from admission (binary endpoint). Because all patients had 
completed follow-up by day 28 (either experienced the endpoint or were discharged), this should 
amount to a reasonable approximation.  
Sex differences in C-reactive protein (CRP), alanine aminotransferase (ALT), lactate dehydrogenase 
(LDH), and serum creatinine were previously found and it was hypothesized that this difference 
could explain the sex-specific clinical characteristics and outcomes (13). We considered the same 
set of biomarkers in this investigation.   
The underlying causal structure of the model is described in Figure 1 through the visual aid of a 
direct acyclic graph (DAG). The hypothesis is that the total effect of sex is the sum of a direct effect 
and of an indirect effect mediated through the burden of exposure to biomarkers over follow-up 
(Figure 1).  The indirect pathway entailed the assumption that males are more likely to be obese 









probability of developing diabetes and other complications of COVID-19 leading to the need of 
invasive ventilation and ultimately death.  
The post-baseline biomarker burden was calculated for each participant and each of the 
biomarkers, using a summary measure for the repeated measures of the markers, as the area 
under the curve (AUC) in follow-up divided per the exact number of days of follow-up. This 
hypothesized model was then in turn separately applied for each of the biomarkers and the 
percentage of the total effect of sex which was explained by the indirect effect pathway was 
calculated.  
For the markers showing the larger mediation effect we also described the AUC values and the 
mean baseline values and slopes over follow-up by sex using a standard mixed linear regression 
model with random intercept and slope. Unsupervised learning was also used to plot the AUC of 
the markers on a plane using the first two principal components in a Principal Component Analysis 
(PCA) in which also individual data points were plotted and labelled by sex. 
Symmetric secondary analyses were performed with endpoints death alone (using a competing 
risk approach including all deaths).  
A two-sided test of less than 0.05 was considered statistically significant. All statistical analyses 
were performed using the SAS software, version 9.4 (Carey USA) apart from the mediation analysis 
which was performed using the command ‘Medeff’ in Stata v16 and unsupervised learning which 
was done using the Factoshiny GUI of the Factorminer library in R. 
Results 
During the study period, 415 patients with severe COVID-19 pneumonia were admitted. Among 
them, 134 were females (32.3%) and 281 males (67.7%). Epidemiological and respiratory 
characteristics are shown in Table 1.   
Females had significantly higher baseline PaO2/FiO2 (254 mmHg vs. 191 mmHg; p=0.023), a lower 
lactate dehydrogenase (LDH=527 vs. 597, p=0.001) and a lower SOFA score (1 vs. 2; p<0.019) 
(Table 2 and 3). In addition, women had a higher platelet counts, but lower haemoglobin, alanine 
aminotransferase, creatinine phosphokinase, calcium and creatinine. The inflammatory profile 
was also better among women who showed lower levels of D-dimer, CRP and ferritin (Table 3).  
By 14 days from admission, 93 males [38.3% (95% CI:31.9-44.7%)] underwent IMV or death while 
by 28 days this proportion increased to 49.2% (95% CI: 39.6-58.9%). The equivalent estimates for 
females were 16.5% (95% CI:8.9-24.2%) and 31.7% (95% CI:17.9-45.4%), respectively (log-rank test 









33.6% (95% CI:25.4-41.8%) in males vs. 20.9% (95% CI:10.1-31.7%) females (log-rank test p-
value=0.06), counting all in-hospital deaths.  
Infections were recorded for a subset of 381 participants (92%). There was a total of 48 infections 
(73% bacterial pneumonias (n=35), 4% bloodstream infections (BSI, n=2), 4% urinary tract 
infections (UTI, n=2) and one female with a dental abscess (0.2%). There was no evidence for an 
unequal distribution of these events by sex (p=0.37). The proportions in males vs. females were 
11% vs. 6% for pneumonia, 1.9% vs. 1.8% for BSI and 1.1% vs. 1.8% for UTI. There were 12 deaths 
that could be attributable to bacterial pneumonias, 10/267 (3.8%) in males and 2/114 (1.8%) in 
females (Fisher exact p=0.52). 
 
Figures  2A/B show the forest plot of the HR for the composite endpoint comparing females with 
males in specific sub-populations, with interaction test p-values. The overall effect of sex on the 
risk of invasive ventilation or death was HR=0.40 (95% 0.26-0.63, p=0.0001) and on mortality alone 
was HR=0.61 (95% 0.36-1.025, p=0.060). There was no evidence that these HR varied in specific 
subpopulations with perhaps the exception of BMI for risk of ventilation/death (HR=0.097, CI 
0.013, 0.711 comparing females with males with a BMI<29.9, interaction p-value =0.04, Figure  
2A).  
Difference in plasma CRP values between males vs. females was 0.32 (p=0.65), as depicted by 
linear mixed regression model (Supplementary Table 1 and Figure 1). 
AUC-CRP over the study period (log10 scale) was 0.51 mg/ml (SD=0.55) in males vs. 0.18 (SD=0.55) 
mg/dl in females (t-test p<0.0001). A similar difference was observed comparing peaks in CRP by 
sex: 1.02 mg/dl in males vs. 0.75 in females (p<0.0001). The burden over follow-up of other 
inflammatory and biochemical markers analysed were higher in males vs. females, namely the 
AUC of IL-6 (2.35 vs. 2.09 p=0.006), LDH (2.78 vs. 2.70, p=0.0008), ferritin (2.89 vs. 2.57, p<0.0001) 
and to a lower extent ALT (1.57 vs. 1.47, p=0.02). Unsupervised learning indicated that 38.7% of 
the variables cloud total variability was explained by the first two dimensions. A cluster in the first 
dimension was characterized by high values for the post baseline AUC of hemoglobin, CRP, 
platelets, ferritin, ALT, IL6 and LDH which matched the location of male individuals 
(Supplementary Figures 2 A/B). 
We finally tested the underlying model depicted by the DAG in Figure 1 by means of a formal 









Table  4A shows that for the direct effect, the risk of IMV and death would decrease, on average, 
by only 2% in females vs. males, under the hypothetical scenario in which all participants would 
keep the CRP level that was seen in males. Therefore, this is an estimate of the sex effect on risk of 
IMV/death which is not explained by post baseline variation in CRP, since this was held fixed and 
appears to be small. In contrast, the estimate of the average indirect effect is much larger and 
indicates that, regardless of sex, the risk of IMV/death is likely to decrease by 10% per one 
mg/dL/day difference in CRP-AUC. When expressed as a relative proportion, the CRP mediation 
effect on sex towards the risk of IMV/death was 85% when considering AUC/day and 53% when 
considering the peak. 
 The AUC mediation effect for other biomarkers, using the same underlying causal structure 
hypothesised for CRP in Figure 1, were 47% for ferritin and 43% for LDH, with much less impact of 
the other biomarkers for which the DAG was much less supported (Table  4A).  
Similar results were observed considering the death end point. Mediation effect was the highest 
for CRP AUC (78% when using AUC, and 74% when using CRP peak), while 64% was the mediation 
effect for LDH and 62% for ferritin. (Table  4B). 
 
Discussion 
This study explores the impact of sex on risk of unfavourable COVID-19 outcomes. In a cohort of 
hospitalized patients with severe COVID-19 pneumonia, we observed a significant lower risk of 
IMV or death in women (60% risk reduction). This signal was also observed with regards to the 
death end point, although data were more compatible with the null hypothesis (HR=0.61, 
p=0.060), probably due to low number of deaths. Our results are consistent with those shown in 
previously published study on sex in COVID-19 (Figure 2) (13). 
Levels of oestrogens may affect ACE2 expression (21) potentially reducing virus entry and 
progression of COVID-19 disease, suggesting that sex difference could be attenuated in the elderly 
population. Nevertheless, sex difference was similar in women aged 70+ (or 50+ in a sensitivity 
analysis).  
BMI resulted an effect modifier of the association between sex and the risk of experiencing the 
composite endpoint. Indeed, females with a BMI<29.9 kg/m
2
, were more protected than males 
with similar BMI from the risk of IMV and death. Explanation for this interaction is unclear, it is 
possible that non-obese men were more likely to be hospitalized because they had greater risk 









Regarding the impact of specific biomarkers, high levels of CRP both at baseline and during follow-
up were explaining most of the difference seen by sex.  
Our key assumption was that sex is randomly allocated at birth so it is a virtually an un-
confounded variable, an assumption which was confirmed by supplementary analyses 
(Supplementary  Figure S3 and Table S2). 
Indeed, the hypothesis that the difference in risk of outcome by sex is only marginally explained by 
our presumed direct pathway acting through oestrogen dependant block of  virus entry by using 
ACE2 receptor. 
We postulated other possible pathways, including one which assumes a mediation effect of 
inflammatory biomarkers. At the basis of this alternative pathway is the innate immune response, 
which leads to the hypothesis of a mediation effect of both IL-6 and CRP. Our data support that 
this pathway is likely to be the leading mediation effect of the sex-difference observed. In detail, 
the AUC of CRP post baseline explains 85% of the difference in clinical progression between sex.  
Of interest, mediation effects explaining >50% of the total sex effect were found for ferritin and 
LDH markers that were both clustering with CRP and male sex by unsupervised learning analysis. 
In contrast, we did not find, as hypothesised in the DAG, any significant mediation effect of D-
dimer which accounted only for a 3% of the sex specific effect. Taken all this together, we argue 
that the majority of difference by sex seen in COVID-19 outcomes is mediated by the effect of CRP. 
 CRP is a well-known marker of inflammation and cardiovascular risk mainly synthesized by 
hepatocytes after stimulation of IL-6 and to a lesser extent IL-1beta (22,23). Moreover, it is a well -
known predictor of COVID-19 complications because it acts as a direct mediator of inflammatory 
reactions and the innate immune response  and it has a tight connection with incident diabetes 
(24). Both these causal links are explicitly indicated in the DAG as the pathways underlying the 
mechanisms of the predominant mediating role of CRP.     
Our study presents several limitations. First, it is an observational study and unmeasured 
confounding cannot be excluded. Second, the magnitude of the effects and the interpretation of 
the results heavily rely on the causal structure hypothesised in the DAG and our simple linear 
model without interactions. Third, despite accurate data collection, BMI and PiO2/FiO2 data were 
missing for some participants and this could have introduced residual confounding and collider 
bias.  
Nevertheless, several points of strengths may be considered. This is the largest study conducted so 









real time resulting in a complete dataset for most variables used in the analysis. Second, the 
underlying causal structure has been transparently depicted using a DAG. Third, to our knowledge, 
this is the first analysis attempting to gain insights into the mechanism that underlies the effect of 
sex on COVID-19 prognosis.  
In conclusion, our study not only confirms a difference in risk of COVID-19 clinical outcome by sex, 
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Table 1 Epidemiological and clinical characteristics by sex 
 
  
                             Sex 




  N= 134 N= 281   N= 415 
Age, years     
 
  
Median (IQR) 69 (54, 79) 65 (55, 76)  0.292 66 (54, 77) 
BMI, Kg/m2     
Median (IQR) 30.1 (25.4, 33.2) 26.2 (24.5, 29.4) 0.009 26.7 (24.7, 30.9) 
Smoking, n(%) 16/41 (39%) 60/113 (53%) 0.14 76/154 (49%) 
Any comorbidity, n(%)     
 
  
Yes 44 (32.8%) 87 (31.0%)  0.701 131 (31.6%) 
Comorbidities, n(%)         
Diabetes 18 (13.4%) 28 (10.0%) 0.293 46 (11.1%) 
Hypertension 39 (29.1%) 79 (28.1%) 0.835 118 (28.4%) 
Cardiovascular Disease 7 (5.2%) 32 (11.4%) 0.044 39 (9.4%) 
Chronic Renal Insufficiency 9 (6.7%) 12 (4.3%) 0.288 21 (5.1%) 
Cancer 6 (4.5%) 7 (2.5%) 0.278 13 (3.1%) 
Hepatitis B/C virus 0 (0.0%) 0 (0.0%) 
 
0 (0.0%) 
Disease Duration         
Days from symptoms onset to 
hospitalisation, median(IQR) 
7 (3, 13) 7 (3, 10) 0.113 7 (3, 11) 
Days from hospitalisation to intubation, 
median(IQR) 
2 (0, 2) 3 (1, 4) 0.104 3 (1, 4) 
Sign and symptoms, n(%)         
Fever, median(IQR) 37 (36, 37) 36 (36, 37) 0.544 36 (36, 37) 
Cough 40 (29.9%) 98 (34.9%) 0.310 138 (33.3%) 
Myalgia 11 (8.2%) 9 (3.2%) 0.026 20 (4.8%) 
Sputum 4 (3.0%) 6 (2.1%) 0.598 10 (2.4%) 
Headache 10 (7.5%) 16 (5.7%) 0.487 26 (6.3%) 
Haemoptysis 0 (0.0%) 3 (1.1%) 0.231 3 (0.7%) 
Systolic pressure, mmHg median(IQR) 120 (110, 130) 125 (110, 135) 0.142 123 (110, 135) 



























Respiratory function, median(IQR)     
Baseline PaO2/FiO2, mmHg 254 (140, 336) 191 (122, 294) 0.023 216 (126, 302) 
Respiratory rate, %  22 (18, 28) 22 (18, 28) 0.893 22 (18, 28) 
 
SOFA Score, median(IQR) 
 
1 (0, 3) 2 (0, 3) 0.019 2 (0, 3) 
Intervention, n(%)     0.248   
Tocilizumab subcutaneous 21 (16.8%) 50 (20.8%)   71 (19.5%) 
Tocilizumab intravenous 20 (16.0%) 25 (10.4%)   45 (12.3%) 
SOC 84 (67.2%) 165 (68.8%)   249 (68.2%) 
Use of Antibiotics 
Events, n (%) 
10/114 (9%) 35/267 (13%) 0.23 45/381 (11.8%) 
Mechanical ventilation 8 (6.0%) 58 (20.6%) <.001 66 (15.9%) 
Death - pre MV 15 (11.2%) 42 (14.9%) 0.300 57 (13.7%) 
Death - all 19 (14.2%) 62 (22.1%) 0.058 81 (19.5%) 



















    N= 123 N= 257   N= 380 
Markers, Median (IQR)           
Haemoglobin, g/dl 380 12.0 (10.5, 13.1) 13.3 (12.1, 14.2) <.001 12.8 (11.4, 14.0) 
White cells, mm3 380 5760 (4540, 8400) 6340 (4930, 8520) 0.274 6110 (4810, 8480) 
Total lymphocytes, N 264 1368 (730.0, 2420) 1584 (870.0, 2390) 0.428 1545 (857.5, 2405) 
Total lymphocytes, % 289 20.2 (7.2, 37.5) 25.4 (11.0, 34.7) 0.525 22.9 (9.1, 35.3) 
Alanine amino-transferase, U/l 225 31.0 (21.0, 44.0) 39.0 (27.0, 58.0) 0.002 35.0 (25.0, 54.0) 
Bilirubin, mg/dl 370 0.4 (0.3, 0.6) 0.6 (0.5, 0.8) <.001 0.6 (0.4, 0.8) 
Calcium, mg/dl 356 8.7 (8.3, 9.1) 8.6 (8.2, 8.9) 0.019 8.6 (8.2, 9.0) 
Creatine Kinase, U/l 375 51.5 (33.0, 108.0) 132.0 (57.0, 282.0) <.001 88.0 (44.0, 221.0) 
Chloride, mmol/l 353 100.0 (98.0, 102.0) 100.0 (98.0, 103.0) 0.575 100.0 (98.0, 103.0) 
Creatinine, mg/dl 380 0.7 (0.6, 0.9) 0.9 (0.8, 1.2) <.001 0.9 (0.7, 1.1) 
D-dimer, ng/ml 375 1015 (640.0, 2070) 1160 (640.0, 2210) 0.591 1150 (640.0, 2170) 
Lactate dehydrogenase, U/l 379 527.0 (397.0, 651.0) 597.0 (461.5, 767.0) 0.001 563.0 (446.0, 726.0) 
C-reactive protein, mg/ml 380 5.8 (2.0, 14.4) 7.5 (4.1, 17.5) <.001 7.0 (3.2, 16.4) 
Platelets, 109/l 380 229.0 (166.0, 292.0) 199.0 (149.0, 269.0) 0.044 207.5 (155.0, 274.5) 
Potassium, mmol/l 369 3.8 (3.5, 4.2) 3.8 (3.5, 4.1) 0.678 3.8 (3.5, 4.1) 
Sodium, mmol/l 369 137.0 (135.0, 139.0) 137.0 (134.0, 139.0) 0.556 137.0 (135.0, 139.0) 
IL-6, pg/ml 262 189.7 (67.4, 366.0) 193.4 (77.2, 399.9) 0.457 191.8 (71.0, 399.9) 
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Figure  2A - HR of mechanical ventilation*/death associated with Sex overall and in subsets from fitting a standard 




*Defintion: Indication for mechanical ventilation were neurologic failure (i.e. altered consciousness with a Glasgow 
Coma Scale score <10), cardiovascular failure (i.e. vasopressor requirement or major ECG changes including arrhythmia 
or changes in repolarization phase) and respiratory failure defined by the presence of at least two of the following 
criteria: respiratory rate >30 bpm, respiratory distress with activation of accessory respiratory muscles,  need for FiO2 at 






























 Risk of invasive ventilation/death Female vs. Male 
 Direct Effect Indirect Effect % of Tot 
Effect 
Mediated 
 % 95% CI % 95% CI % 
Biomarker (per log10 higher)      
      
Total lymphocytes, AUC -11% -21%; 0% 0% -2%; +2% 0.5% 
Alanine amino-transferase, AUC -15% -24%; -5% +2% 0%; +5% -18% 
D-dimer, AUC -13% -22%; -3%   -0.4% -1%; 0% 3% 
Lactate dehydrogenase, AUC -7% -16%; +3% -5% -10%;-1%  43% 
C-reactive protein, AUC -2% -11%; +8%  -10% -16%; -6% 85% 
C-reactive protein, peak -7% -16%; +3% -7% -12%; -4%  53% 
Platelets, AUC -12% -21%; -2%   -2% -5%; -1% 16% 
IL-6, AUC -16% -26%; -5% -4% -8%; 0% 18% 
Ferritin, AUC -4% -16%; +8% -5% -10%; 0% 47% 
Haemoglobin, AUC -19% -27%; -1% +1% 0%; +5% -10% 





 Risk of death Female vs. Male 
 Direct Effect Indirect Effect % of Tot 
Effect 
Mediated 
 % 95% CI % 95% CI % 
Biomarker (per log10 higher)      
      
Total lymphocytes, AUC -6% -16%; +5% 0% -1%; +2% 0.5% 
Alanine amino-transferase, AUC -4% -15%; +8% -2% -4%; 0% 19% 
D-dimer, AUC -9% -16%; 0%   -1% -0.3%; 0% 14% 
Lactate dehydrogenase, AUC -3% -11%; +6% -6% -10%;-2%  64% 
C-reactive protein, AUC -2% -10%; +6%  -7% -12%; -4% 78% 
C-reactive protein, peak -3% -10%; +5% -9% -13%; -5%  74% 
Platelets, AUC -8% -16%; 0%   0% -3%; -1% 10% 
IL-6, AUC -11% -20%; 0% -4% -5%; 0% 16% 
Ferritin, AUC 0% -10%; +12% -4% -10%; -1% 62% 
Haemoglobin, AUC -11% -19%; -2% +2% 0%; +5% -28% 



















Estimates from the mixed model (Mean values 95% CI) - log10 scale 















Sex             
















    <.001   0.798   0.648 
*
Adjusted for age and total SOFA Score 
 
Supplementary Table S2 




Unadjusted and adjusted relative hazards of mechanical 
ventilation/death 
  N 
No. 
events 
RH (95% CI) p-value 
RH of female vs. male         
Unadjusted 415 123 0.40 (0.26, 0.63) <.001 
Adjusted
1
 331 82 0.40 (0.22, 0.71) 0.002 
Adjusted
2
 299 69 0.42 (0.22, 0.79) 0.007 
Adjusted
3
 203 52 0.33 (0.15, 0.70) 0.004 
Adjusted
4
 295 69 0.40 (0.21, 0.75) 0.004 
Adjusted
5
 161 35 0.25 (0.09, 0.67) 0.006 
1
adjusted for age, Charlson Index, Sofa Score and duration of symptoms 
2
adjusted for factors included in (1) plus baseline CRP 
3
adjusted for factors included in (1) plus baseline IL-6 
4
adjusted for factors included in (1) plus baseline d-dimer 
5
































14 days period from date of admission










Supplementary Figure 2 
 
 



























Supplementary Figure S3 
Weighted Kaplan-Meier Curve comparing the cumulative risk of mechanical ventilation or death 
by sex 
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